TONKA Versus Legalon for Lowering Hepatic Enzymes in Liver Function Disorder Patients.
Launched by NHAT NHAT PHARMACEUTICAL COMPANY · Jul 11, 2017
Trial Information
Current as of July 06, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and Female more than 18 year old.
- • Diagnosed as Alcoholic Liver Disease (ALD), or Non Alcoholic Fatty Liver Disease (NAFLD), or Liver Function Disorders due to Drugs or Chemicals.
- • ALT at baseline is in between 150 U/L to 400 U/L
- • Sign the informed consent form
- Exclusion Criteria:
- • Hepatitis B or C.
- • Pregnant or Lactating women
About Nhat Nhat Pharmaceutical Company
Nhat Nhat Pharmaceutical Company is a dynamic leader in the pharmaceutical industry, dedicated to advancing healthcare through innovative drug development and clinical research. With a commitment to improving patient outcomes, the company focuses on creating high-quality, effective therapeutic solutions across various medical disciplines. Nhat Nhat Pharmaceutical Company prioritizes scientific excellence, regulatory compliance, and ethical practices in its clinical trials, fostering collaboration with healthcare professionals and research institutions. By leveraging cutting-edge technology and a robust pipeline, Nhat Nhat aims to address unmet medical needs and contribute to the global health landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hue, , Vietnam
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials